CLEC9A and neoplasm: The cDC1s are distinguished from other DC subsets by their expression of BDCA3/CD141, XCR1 and DNGR1/Clec9α [10], and their higher potential for cross-presentation through their MHC-I—allowing them to induce effective cytotoxic immune responses against tumor cells after the recognition of tumor antigens (derived from dying tumor cells) by CD8 T-cells [11].